GGrantIndex
← Leaderboards

Jeffrey M Jacobson

Case Western Reserve University

$26,342,255
Attributed
$26,818,456
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.1M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$27,835,542 · 8

By mechanism

UM1$13,409,128 · 1
U01$6,643,692 · 2
R01$3,420,651 · 1
U19$1,800,394 · 1
P30$1,671,429 · 1
R56$483,000 · 1

Top collaborators

Most similar at Case Western Reserve University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchMonitorEpidemicHiv InfectionsResearch PersonnelAids Clinical Trial GroupAnti-Retroviral AgentsSuccessUniversitiesPathogenesisPersonsCollaborationsSiteEnrollmentPreventionLaboratoriesAntiretroviral TherapyLifePharmaceutical PreparationsTranslational ResearchLinkInternationalAreaProtocols Documentation

Grant awards (26)

Core D: Clinical Sciences$423,040
P30 · FY2025 · AI · contact PI
Case Clinical Trials Unit$308,403
UM1 · FY2025 · AI
Case Clinical Trials Unit$2,393,908
UM1 · FY2024 · AI · contact PI
Core D: Clinical Sciences$419,795
P30 · FY2024 · AI · contact PI
Case Clinical Trials Unit$2,436,364
UM1 · FY2023 · AI · contact PI
Core D: Clinical Sciences$408,139
P30 · FY2023 · AI · contact PI
Case Clinical Trials Unit$2,582,654
UM1 · FY2022 · AI · contact PI
Innate and adaptive defenses against SARS-COV-2 in the oral cavity during acute unvaccinated and breakthrough infections$483,000
R56 · FY2022 · DE
Core D: Clinical Sciences$420,455
P30 · FY2022 · AI · contact PI
Case Clinical Trials Unit$2,575,678
UM1 · FY2021 · AI · contact PI
Case Clinical Trials Unit$3,112,121
UM1 · FY2020 · AI · contact PI
Long-Acting HIV Therapy for Injection Drug Users$557,141
R01 · FY2014 · DA · contact PI
Long-Acting HIV Therapy for Injection Drug Users$63,220
R01 · FY2014 · DA · contact PI
Long-acting, self-administered HIV therapy with th CCR5 antibody PRO 140$2,600,308
U01 · FY2013 · AI · contact PI
Long-Acting HIV Therapy for Injection Drug Users$645,026
R01 · FY2013 · DA · contact PI
Long-Acting HIV Therapy for Injection Drug Users$699,093
R01 · FY2012 · DA · contact PI
Long-acting, self-administered HIV therapy with th CCR5 antibody PRO 140$3,026,298
U01 · FY2011 · AI · contact PI
Long-Acting HIV Therapy for Injection Drug Users$715,774
R01 · FY2011 · DA · contact PI
Sphingolipids as a Novel Therapy for Radiation Lung Injury$407,248
P01 · FY2011 · HL · contact PI
Long-Acting HIV Therapy for Injection Drug Users$740,397
R01 · FY2010 · DA · contact PI
HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140$402,394
U19 · FY2008 · AI · contact PI
HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140$394,071
U19 · FY2007 · AI · contact PI
HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140$692,461
U19 · FY2006 · AI · contact PI
HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140$311,468
U19 · FY2005 · AI
ADULT AIDS CLINICAL TRIALS UNIT$286,833
U01 · FY2001 · AI
ADULT AIDS CLINICAL TRIALS UNIT$730,253
U01 · FY2000 · AI